Stories
Stories
Alumni-Led Biotech Developing Vaccine to Combat Coronavirus
Photo by Richard Howard
Photo by Richard Howard
As reported in the Boston Globe, Stéphane Bancel (MBA 2000, AMP 170) and his firm Moderna Therapeutics are working with the National Institutes of Health (NIH) to develop a vaccine for coronavirus. Vials of its vaccine, the company told the Globe, have been sent to the NIH for testing. An article in the Wall Street Journal notes that the NIH expects clinical trials to begin in 20 to 25 volunteers by the end of April.
Bancel is also part of a wider effort by researchers from Harvard and other local higher ed institutions to combat the spread of the coronavirus. As the Globe notes, dozens of prominent local scientists and biotech leaders—Bancel included—met this week at Harvard Medical School to brainstorm new approaches. That meeting is part of a recently announced $115 million collaboration between scientists at Harvard Medical School and their colleagues in China to help address the threat of the coronavirus.
Post a Comment
Related Stories
-
- 01 Mar 2025
- HBS Magazine
Origin Story: Ricky Cordova (MS/MBA 2025)
Re: Jannine Versi (MBA 2014); Laura Mackay (MBA 2014); By: Julia Hanna -
- 24 Jan 2025
- Making A Difference
The Network Effect
Re: Karan Mathur (MBA 2015); Dina Model (MBA 2015) -
- 16 Sep 2024
- Making A Difference
Life Preserver
Re: Sebastian Eriksson Giwa (MBA 2009) -
- 04 Apr 2024
- HBS Alumni News
The Making of a Medical Milestone
Re: D.A. Gros (MBA 2002); By: Margie Kelley
Stories Featuring Stefan Bancel
-
- 10 Jun 2022
- Live from Klarman Hall
Building an AI-First Biotech Company
Re: Stefan Bancel (MBA 2000); Karim R. Lakhani (Dorothy and Michael Hintze Professor of Business Administration) -
- 17 Jun 2021
- Newsweek
A Conversation With Moderna Leader Stéphane Bancel
Re: Stefan Bancel (MBA 2000) -
- 20 Jan 2021
- HBS Clubs
In Conversation with Stéphane Bancel
Re: Stefan Bancel (MBA 2000)
More Stories Featuring Stefan Bancel
